Synonym
PD-198306; PD 198306; PD198306.
IUPAC/Chemical Name
Benzamide, N-(cyclopropylmethoxy)-3,4,5-trifluoro-2-((4-iodo-2-methylphenyl)amino)-
InChi Key
UHAXDAKQGVISBZ-UHFFFAOYSA-N
InChi Code
InChI=1S/C18H16F3IN2O2/c1-9-6-11(22)4-5-14(9)23-17-12(7-13(19)15(20)16(17)21)18(25)24-26-8-10-2-3-10/h4-7,10,23H,2-3,8H2,1H3,(H,24,25)
SMILES Code
O=C(NOCC1CC1)C2=CC(F)=C(F)C(F)=C2NC3=CC=C(I)C=C3C
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Biological target:
PD 198306 is a selective MAPK/ERK-kinase (MEK) inhibitor.
In vivo activity:
Intrathecal administration of the selective MAPK/ERK-kinase (MEK) inhibitor PD 198306 dose-dependently (1-30 micro g) blocked static allodynia in both the streptozocin and the chronic constriction injury (CCI) rat models of neuropathic pain. The antihyperalgesic effects of PD 198306, in both the streptozocin and CCI models of neuropathic pain, correlated with a reduction in the elevated levels of active ERK1 and 2 in lumbar spinal cord.
Reference: Br J Pharmacol. 2003 Mar;138(5):751-6. https://pubmed.ncbi.nlm.nih.gov/12642375/
|
Solvent |
mg/mL |
mM |
| Solubility |
| DMSO |
47.9 |
100.00 |
| Ethanol |
47.6 |
100.00 |
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.
Preparing Stock Solutions
The following data is based on the
product
molecular weight
476.24
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
Formulation protocol:
1. Pelletier JP, Fernandes JC, Brunet J, Moldovan F, Schrier D, Flory C, Martel-Pelletier J. In vivo selective inhibition of mitogen-activated protein kinase kinase 1/2 in rabbit experimental osteoarthritis is associated with a reduction in the development of structural changes. Arthritis Rheum. 2003 Jun;48(6):1582-93. doi: 10.1002/art.11014. PMID: 12794826.
2. Ciruela A, Dixon AK, Bramwell S, Gonzalez MI, Pinnock RD, Lee K. Identification of MEK1 as a novel target for the treatment of neuropathic pain. Br J Pharmacol. 2003 Mar;138(5):751-6. doi: 10.1038/sj.bjp.0705103. PMID: 12642375; PMCID: PMC1573714.
In vivo protocol:
1. Pelletier JP, Fernandes JC, Brunet J, Moldovan F, Schrier D, Flory C, Martel-Pelletier J. In vivo selective inhibition of mitogen-activated protein kinase kinase 1/2 in rabbit experimental osteoarthritis is associated with a reduction in the development of structural changes. Arthritis Rheum. 2003 Jun;48(6):1582-93. doi: 10.1002/art.11014. PMID: 12794826.
2. Ciruela A, Dixon AK, Bramwell S, Gonzalez MI, Pinnock RD, Lee K. Identification of MEK1 as a novel target for the treatment of neuropathic pain. Br J Pharmacol. 2003 Mar;138(5):751-6. doi: 10.1038/sj.bjp.0705103. PMID: 12642375; PMCID: PMC1573714.
1: Ye Q, Hickey J, Summers K, Falatovich B, Gencheva M, Eubank TD, Ivanov AV, Guo NL. Multi-Omics Immune Interaction Networks in Lung Cancer Tumorigenesis, Proliferation, and Survival. Int J Mol Sci. 2022 Nov 29;23(23):14978. doi: 10.3390/ijms232314978. PMID: 36499305; PMCID: PMC9738413.
2: Hong J, Zheng W, Cai X. Small-molecule High-throughput Screening Identifies an MEK Inhibitor PD198306 that Enhances Sorafenib Efficacy via MCL-1 and BIM in Hepatocellular Carcinoma Cells. Comb Chem High Throughput Screen. 2023;26(7):1364-1374. doi: 10.2174/1386207325666220830145026. PMID: 36043792; PMCID: PMC9971357.
3: Besson B, Kim S, Kim T, Ko Y, Lee S, Larrous F, Song J, Shum D, Grailhe R, Bourhy H. Kinome-Wide RNA Interference Screening Identifies Mitogen-Activated Protein Kinases and Phosphatidylinositol Metabolism as Key Factors for Rabies Virus Infection. mSphere. 2019 May 22;4(3):e00047-19. doi: 10.1128/mSphere.00047-19. PMID: 31118297; PMCID: PMC6531879.
4: Franklin JM, Carrasco GA. Cannabinoid receptor agonists upregulate and enhance serotonin 2A (5-HT(2A)) receptor activity via ERK1/2 signaling. Synapse. 2013 Mar;67(3):145-59. doi: 10.1002/syn.21626. Epub 2012 Dec 8. PMID: 23151877; PMCID: PMC3552103.
5: Aksamitiene E, Kholodenko BN, Kolch W, Hoek JB, Kiyatkin A. PI3K/Akt- sensitive MEK-independent compensatory circuit of ERK activation in ER-positive PI3K-mutant T47D breast cancer cells. Cell Signal. 2010 Sep;22(9):1369-78. doi: 10.1016/j.cellsig.2010.05.006. Epub 2010 May 12. PMID: 20471474; PMCID: PMC2893265.
6: Pelletier JP, Fernandes JC, Brunet J, Moldovan F, Schrier D, Flory C, Martel- Pelletier J. In vivo selective inhibition of mitogen-activated protein kinase kinase 1/2 in rabbit experimental osteoarthritis is associated with a reduction in the development of structural changes. Arthritis Rheum. 2003 Jun;48(6):1582-93. doi: 10.1002/art.11014. PMID: 12794826.
7: Ciruela A, Dixon AK, Bramwell S, Gonzalez MI, Pinnock RD, Lee K. Identification of MEK1 as a novel target for the treatment of neuropathic pain. Br J Pharmacol. 2003 Mar;138(5):751-6. doi: 10.1038/sj.bjp.0705103. PMID: 12642375; PMCID: PMC1573714.
